AF
IOVA icon

Advisornet Financial’s Iovance Biotherapeutics IOVA Stock Holding History

Advisornet Financial’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$4K – 2086
2021
Q4 		$4K Hold
200
– – ﹤0.01% 1700
2021
Q3 		$5K Hold
200
– – ﹤0.01% 1618
2021
Q2 		$5K Hold
200
– – ﹤0.01% 1568
2021
Q1 		$6K Hold
200
– – ﹤0.01% 1478
2020
Q4 		$9K Sell
200
-300
-60% -$11.9K ﹤0.01% 1313
2020
Q3 		$17K Hold
500
– – ﹤0.01% 1141
2020
Q2 		$13K Buy
+500
New +$16.4K ﹤0.01% 1227

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisornet Financial's IOVA Position: Q4 2025 in Review

Advisornet Financial sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 74 shares — an estimated $161 sold.

Advisornet Financial first reported a position in IOVA in Q1 2019 and held it in 14 quarters. The position peaked at $547K in Q4 2020. 264 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

  • Advisornet Financial reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Advisornet Financial sold 74 Iovance Biotherapeutics shares in Q4 2025, an estimated $161.
  • Advisornet Financial first reported a position in Iovance Biotherapeutics in Q1 2019 and held it in 14 quarters.
  • Advisornet Financial's Iovance Biotherapeutics position peaked at $547K in Q4 2020.
  • 264 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on Advisornet Financial's 13F filing for Q4 2025, filed 20 Jan 2026.